{ "meta": { "data_length": 1, "message": "Statement id stmt:ema:zydelig:0:2 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Azydelig%3A0%3A2", "status": "success", "status_code": 200, "timestamp_elapsed": 0.00229, "timestamp_received": "2026-10-16T22:57:44.566753+00:00Z", "timestamp_returned": "2026-10-16T22:57:44.569043+00:00Z", "trace_id": "4eaa044a-9f6b-491e-8e24-7e3c826c12dd" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:ema:zydelig:0:2", "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2014-09-18:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2014-09-18", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:zydelig", "type": "Document", "documentType": "Regulatory approval", "name": "Zydelig (idelalisib) [product information]. EMA.", "title": null, "aliases": [], "description": "Gilead Sciences Ireland UC. Zydelig (idelalisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf. Revised June 2023. Accessed March 26, 2024.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Gilead Sciences Ireland UC.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Zydelig", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "idelalisib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2014-10-14", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2023-06-23", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:714", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C3163", "conceptType": "Disease", "name": "Chronic Lymphocytic Leukemia", "mappings": [ { "relation": "closeMatch", "coding": { "id": "coding:ncit:C7540", "code": "C7540", "name": "Small Lymphocytic Lymphoma", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C7540" ] } }, { "relation": "broadMatch", "coding": { "id": "coding:oncotree:CLLSLL", "code": "CLLSLL", "name": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Chronic+Lymphocytic+Leukemia%2FSmall+Lymphocytic+Lymphoma+%28CLLSLL%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": false, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C3163", "code": "C3163", "name": "Chronic Lymphocytic Leukemia", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3163" ] } }, "objectTherapeutic": { "id": "txgrp:145", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C78825", "conceptType": "Therapy", "name": "Idelalisib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1544460", "code": "1544460", "name": "idelalisib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1544460" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:45776944", "code": "45776944", "name": "idelalisib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/45776944" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "PI3K/AKT/mTOR inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C78825", "code": "C78825", "name": "Idelalisib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C78825" ] } }, { "id": "tx:ncit:C1702", "conceptType": "Therapy", "name": "Rituximab", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:121191", "code": "121191", "name": "rituximab", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=121191" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1314273", "code": "1314273", "name": "rituximab", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1314273" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "CD20 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C1702", "code": "C1702", "name": "Rituximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:82", "present": true, "subject": { "id": "bmkr:82", "type": "CategoricalVariant", "name": "17p deletion", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.qfCTfkL3D4_EYfMm-vNUV3gPBn6POGaV", "type": "SequenceLocation", "name": null, "aliases": [], "description": "The p arm of GRCh38 chromosome 17 (NC_000017.11), from the start of the chromosome to the start of the centromere.", "digest": "qfCTfkL3D4_EYfMm-vNUV3gPBn6POGaV", "sequenceReference": { "id": "ga4gh:SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7", "type": "SequenceReference", "name": "NC_000017.11", "aliases": [ "ga4gh:SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7", "refseq:NC_000017.11" ], "description": "GRCh38 chromosome 17 (RefSeq NC_000017.11).", "moleculeType": "genomic", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7", "residueAlphabet": "na" }, "start": 0, "end": 22813679, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "CopyChangeConstraint", "copyChange": "loss" } ], "extensions": [ { "name": "biomarker_type", "value": "Copy number (arm level)" }, { "name": "chromosome", "value": "17" }, { "name": "arm", "value": "p" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:ema:zydelig:0", "type": "Indication", "description": "Zydelig is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2014-09-18:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2014-09-18", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:zydelig", "type": "Document", "documentType": "Regulatory approval", "name": "Zydelig (idelalisib) [product information]. EMA.", "title": null, "aliases": [], "description": "Gilead Sciences Ireland UC. Zydelig (idelalisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf. Revised June 2023. Accessed March 26, 2024.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Gilead Sciences Ireland UC.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Zydelig", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "idelalisib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2014-10-14", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2023-06-23", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }